COMP <GO>
CORT vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Corcept Therapeutics Incorporated (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CORT 3
— JNJ 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $85.95 (-0.38%) • MKT CAP: $9.29B
roic
4.80%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 67.90% | +28.10 | CORT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 4.80% | 25.50% | -20.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 18.5x | +76.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | 2.97% | -1.44 | JNJ | /fcf-yield <GO> |
| Operating Margin | 5.90% | 34.70% | -28.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 28.50% | -15.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 6.00% | +6.80 | CORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 62.1 | -31.20 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.08 | -0.20 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.3x | 23.0x | +55.30 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.29B | $662.49B | -$653.20B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | JNJ REV | CORT GROSS % | JNJ GROSS % | CORT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $94.19B | 98.3% | 67.9% | $141.8M | $19.70B |
| FY 2024 | $675.0M | $88.82B | 98.4% | 69.1% | $196.1M | $19.84B |
| FY 2023 | $482.4M | $85.16B | — | — | $105.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
JNJ // BETA 1.08